SCHEDULE: State Street Discloses 6.3% Stake in Xencor Inc.

State Street Corporation has reported a 6.3% beneficial ownership stake in Xencor Inc. common stock as of December 31, 2025.

Summary

• State Street Corporation, a parent holding company, beneficially owns 4,507,254 shares of Xencor Inc. common stock.
• This represents 6.3% of Xencor Inc.'s outstanding common stock.
• State Street Corporation holds shared voting power over 4,308,425 shares and shared dispositive power over 4,507,254 shares.
• The filing was made pursuant to Rule 13d-1(b), indicating passive investment intent.
• The beneficial ownership is held through various subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant passive stake by a large institutional investor like State Street Corporation can be interpreted as a vote of confidence, without implying active influence or specific operational endorsement.

Positives

• A major financial institution, State Street Corporation, holds a significant passive stake, which can be interpreted as a vote of confidence in Xencor Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership by major financial players like State Street Corporation can often signal a degree of confidence in a company's long-term prospects within its industry, though this filing itself does not provide operational details or strategic insights into Xencor Inc.'s position in the biotechnology sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially enhancing market stability and liquidity.

Key Dates

Recommendation

The filing indicates a significant passive stake by State Street Corporation, a major institutional investor. While this suggests a degree of confidence, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' is appropriate as it signals institutional presence without new performance insights.

Keywords

Xencor Inc, State Street Corporation, Schedule 13G, common stock, beneficial ownership, institutional investment, biotechnology, pharmaceuticals